Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBO vs CLYM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–4 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBO 4 – 0 CLYM (2 Tie) Matrix Metrics: IBO 5 – 4 CLYM

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas CLYM carries 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and CLYM (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBO vs CLYM
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol -6.75β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$10.00
-3.47% 1D
Market Cap $638.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.50β · 114% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $10.28 · SMA50: $11.47

6-Pillar Scorecard Institutional Category Breakdown (IBO 4 – 0 CLYM)

Columns: Metric · IBO · CLYM
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 18.2x N/M
2. Growth & Scale IBO
Revenue Growth (YoY) +16.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $41.2M $638.5M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin -12621.0% 0.0%
Net Profit Margin 4247.4% 0.0%
Return on Equity (ROE) 71.2% -29.3%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$99M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.18 Book/Sh · 71.2% ROE $3.95 Book/Sh · -29.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBO (5) vs CLYM (4)
Institutional Metric IBO CLYM Criterion Row Edge
Market Capitalization
Scale
$41.2M $638.5M Larger Scale CLYM
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.7% +0.0% Higher Growth IBO
Operating Margin (TTM)
Profitability
-12621.0% 0.0% Higher Margin CLYM
Net Profit Margin
Profitability
4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
71.2% -29.3% Higher ROE IBO
52-Week Range Position
Momentum
68% ($0–$7) 50% ($2–$18) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
-6.75β · 120% Vol 1.50β · 114% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 41.9 / 100 (SELL) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$99M ($1.18 Book/Sh · 71.2% ROE) N/A ($3.95 Book/Sh · -29.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +83.24 pp
IBO: +85.07% · CLYM: +1.83%
3M Horizon IBO +997.82 pp
IBO: +955.32% · CLYM: -42.5%
6M Horizon IBO +820.21 pp
IBO: +821.42% · CLYM: +1.21%
1Y Horizon IBO +437.79 pp
IBO: +872.55% · CLYM: +434.76%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs CLYM. Trailing 12-month operating profitability (IBO -12621.0% vs CLYM 0.0%) and valuation multiples (IBO N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M
CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $41.2M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $638.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBO vs CLYM Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas CLYM carries 41.9/100 (SELL) at $10.00 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CLYM currently prints a higher short-term Unified Composite Score (41.9/100 SELL vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY). Defensive Composite Rating Caution: Although IBO compares more favorably head-to-head, both IBO (36.8/100 SELL) and CLYM (41.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.

IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus CLYM (-29.3% ROE) capital efficiency.

In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.